Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
about
Radioresistance of Brain TumorsRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsAttributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.Strategies for improving the reporting of human immunophenotypes by flow cytometry.Interaction of radiation therapy with molecular targeted agentsThe mTOR signaling pathway as a treatment target for intracranial neoplasmsThe challenges and the promise of molecular targeted therapy in malignant gliomas.Impact of temozolomide on immune response during malignant glioma chemotherapyRisk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitorsCombining molecular targeted agents with radiation therapy for malignant gliomasIL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer.Temsirolimus: a safety and efficacy review.Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Targeted therapy in gliomas.Toward precision medicine in glioblastoma: the promise and the challenges.Investigational new drugs for brain cancer.Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment.Radiation-induced esophagitis exacerbated by everolimus.Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas.Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.
P2860
Q26752579-7F23B9FA-13EA-4767-A304-A5979DF9C4F5Q26851417-4437E84C-B9A7-4F01-A29D-79322D497765Q30243969-E624D5BE-EE39-4BF2-86B1-F53F8FF3E2B6Q33404027-9B978893-03FF-4D4D-B20F-90D1C1EB1272Q33408116-F0A0FE0F-E2A9-403B-A070-0F0512ED179BQ33411585-BD384FAF-063B-4B74-BE89-6F4AB0EB4C54Q33822690-1C9078CF-6F5E-4D9D-9804-4F8AAEBB476BQ34124285-DB0C6FEB-C61C-42CC-9358-6EC1F0FEA1C0Q34886859-29851D00-674E-4CD4-9EAA-3855D3EC3D65Q35214534-730A0079-F2C4-48C5-89C4-6E4377CA39F3Q36362798-EA32AE38-4A63-4B7B-A31A-B5CCE571DAF2Q36959193-6DC66A7A-4D1E-4FCC-AE4A-A43FDCEE1F5AQ37099594-2490CDC4-6AFD-46F2-9CC2-F48C6A9DE3A1Q37261189-3EBF1881-4AF1-4EE1-898C-CE64B388E18CQ37728090-E1F3E92C-D822-40A8-A433-F9403F5A9A5EQ38031941-66B4F11B-1306-4F91-AC4C-6ABCA2A7C98EQ38102636-20B28320-C4A9-448C-AAE2-88727703DAF3Q38108186-AEDB20FE-E59E-4DE4-853D-2A36753325F0Q38186656-B548F89D-995C-4026-8D93-A75FCE414DD9Q38454659-91FDCED4-C00E-46E9-A547-2DE106A98407Q38832510-754F0B03-B5A4-4F13-A9B2-908ED2FD4AC6Q39352989-E8D6049F-1897-4B05-AFA3-50C3F4BE9EA9Q41889900-F85D24EC-5559-4F81-A59C-D15A1DC92632Q48009516-E255E029-BB53-461F-AE6B-D9D376E4DD4AQ48155956-67886172-BF92-4270-8FE6-42510C735A32Q50068283-A9B5266A-B867-4CE0-A6CD-A3AAD8215942
P2860
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Combination of temsirolimus (C ...... ith increased infectious risks
@ast
Combination of temsirolimus (C ...... ith increased infectious risks
@en
Combination of temsirolimus
@nl
type
label
Combination of temsirolimus (C ...... ith increased infectious risks
@ast
Combination of temsirolimus (C ...... ith increased infectious risks
@en
Combination of temsirolimus
@nl
prefLabel
Combination of temsirolimus (C ...... ith increased infectious risks
@ast
Combination of temsirolimus (C ...... ith increased infectious risks
@en
Combination of temsirolimus
@nl
P2093
P2860
P1476
Combination of temsirolimus (C ...... ith increased infectious risks
@en
P2093
Caterina Giannini
Eva Galanis
Jan C Buckner
Jann N Sarkaria
Joon H Uhm
Kurt A Jaeckle
Laurence Doyle
Michael P Gustafson
Paul D Brown
Ravi D Rao
P2860
P304
P356
10.1158/1078-0432.CCR-10-1453
P407
P577
2010-10-04T00:00:00Z